DC-CIK cell therapy combined with transcatheter arterial chemoembolization and radiofrequency ablation for treatment of small hepatocellular carcinoma

Zhang, Quancheng

doi:10.11569/wcjd.v22.i16.2237

Cited by 6 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eight studies used CIKs-only immunotherapy to treat patients in the study group. Other four studies evaluated the efficacy of CIK-based cytotherapy as follows: Xu et al [ 17 ] used dendritic cells (DCs), γδ T cells plus CIKs; Zhang et al [ 18 ] used DCs plus CIKs; Cui et al [ 19 ] used NK cells, CIKs and γδ T-cells. Qiu et al [ 20 ] used CIKs plus α-Gal epitope-expressing tumor cell-pulsed DCs.…”

Section: Resultsmentioning

confidence: 99%

Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review

Cai

Lin

et al. 2017

Oncotarget

View full text Add to dashboard Cite

BackgroundHigh recurrence rate after curative treatment is the major problem for hepatocellular carcinoma (HCC). Cytokine-induced killer cells (CIKs) therapy was extensively studied among HCC patients. However, the value of CIKs therapy was controversial. A meta-analysis was performed to investigate the efficacy of adjuvant CIKs after invasive treatments among HCC patients.MethodsWe searched online for literatures studying sequential CIKs therapy for HCC patients. Recurrence-free survival (RFS), progress-free survival (PFS) and overall survival (OS) were set as the main endpoints. Both overall and subgroup analysis were accomplished.ResultsA total of 12 clinical trials with 1,387 patients were included. The pooled analysis showed a significant improvement of RFS, PFS and OS in CIK group (HR 0.56, 95% CI 0.47-0.67, p<0.00001 for RFS; HR 0.53, 95% CI 0.40-0.69, p<0.00001 for PFS; HR 0.59, 95% CI 0.46-0.77, p<0.0001 for OS). The proportion of CD4+ T cells increased significantly, while CD8+ T cells decreased significantly after CIKs therapy (WMD 4.07, 95% CI 2.58-5.56, p<0.00001; WMD -2.84, 95% CI -4.67 to -1.01, p=0.002, respectively). No significant differences of adverse events between CIK and non-CIK group existed.ConclusionsConventionally invasive therapies combined with CIKs therapy could improve the prognosis of HCC patients, especially for RFS and PFS, with mild side effects. Optimizing patient selection shall be the direction in future studies.

show abstract

Section: Resultsmentioning

confidence: 99%

Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review

Cai

Lin

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…The 19 included papers comprised 11 randomized controlled studies [20–22,26,28,29,32,34,35,37,38], 1 studies without describing the randomization method [25] and 7 retrospective studies with a matched-pair control group [23,24,27,30,31,33,36]. It contained eleven (57.89%) with all low risk of bias, one (5.26%) with unclear risk and seven (36.84%) with high risk of bias in random sequence generation, allocation concealment, blinding of participants and personnel and blinding of outcome assessment items, as was shown in S1 Fig.…”

Section: Resultsmentioning

confidence: 99%

Is Adjuvant Cellular Immunotherapy Essential after TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma? A Systematic Meta-Analysis of Studies Including 1774 Patients

et al. 2016

View full text Add to dashboard Cite

PurposeCellular immunotherapy has appeared to be a promising modality for the treatment of malignant tumor. The objective of this study was to evaluate the efficacy of cellular immunotherapy combined with minimally invasive therapy.MethodsWe searched PubMed, Web of Science and The Cochrane Library through March 2016 for relevant studies. Short-term efficacy (the disease control rate, the control rate of quality life and the AFP descent rate) and long-term efficacy (overall survival (OS) and progression-free survival (PFS) rate) were compared as the major outcome measures. The meta-analysis was performed using Review Manager 5.3.ResultsA total of 1174 references in 3 databases were found of which 19 individual studies with 1774 HCC patients enrolled in this meta-analysis. Meta-analysis results showed that cellular immunotherapy combined with minimally-invasive treatment significantly improved the measures of short-term response (the disease control rate (OR = 5.91, P = 0.007), the control rate of quality lift (OR = 3.38, P = 0.003) and the AFP descent rate (OR = 4.48, P = 0.02)). Also higher 6-month PFS (OR = 2.78, P = 0.05), ≥12-month PFS (OR = 3.56, P<0.00001) rate and 6-month OS (OR = 2.81, P = 0.0009), 12-month OS (OR = 3.05, P<0.00001) and 24-month OS (OR = 3.52, P<0.0001) rate were observed in patients undergoing cellular immunotherapy.ConclusionsThis meta-analysis suggested that cellular immunotherapy is a feasible adjuvant treatment that could be beneficial for the improvement of the clinical outcomes for hepatocellular carcinoma (HCC) patients after minimally invasive treatment, including short-term response and long-term survival.

show abstract

“…All trials originated from China. The types of cancer treated within the trials were lung cancer (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22), hepatic carcinoma (23)(24)(25)(26)(27)(28)(29), gastric carcinoma (30)(31)(32)(33)(34)(35)(36)(37), metastatic brain carcinoma (38,39), leukemia (40)(41)(42)(43)(44), and osteogenic sarcoma (45). The objective outcome measures were ORR (8)(9)(10)(11)(12)(13)(14)(15)(16), CB (8-10, 12-16, 18-22, 24-26, 28-33, 35-37, 40-44), SR (12,…”

Section: Resultsmentioning

confidence: 99%

“…The pooled results did not show Four trials compared the effects of elemene plus chemotherapy with chemotherapy alone on 1-year SR in patients with lung cancer (12,16,17,21), and two trials assessed the effects with hepatic carcinoma (24,29). heterogeneity: χ 2 = 0.64, p = .89, I 2 = 0%, Figure 4 …”

Section: Survivalmentioning

confidence: 99%

“…Two trials compared the effects of elemene plus chemotherapy with chemotherapy alone on 6-month SR in patients with hepatic carcinoma (24,29). The pooled results did not show Four trials compared the effects of elemene plus chemotherapy with chemotherapy alone on 1-year SR in patients with lung cancer (12,16,17,21), and two trials assessed the effects with hepatic carcinoma (24,29).…”

Section: Survivalmentioning

confidence: 99%

See 1 more Smart Citation

Elemene, One Ingredient of a Chinese Herb, Against Malignant Tumors: A Literature-based Meta-analysis

Zheng

et al. 2013

Cancer Investigation

View full text Add to dashboard Cite

We sought to evaluate the efficacy of elemene in cancer treatment. We searched the literature using several databases up to October 2011. Thirty-eight trials met inclusion criteria. The meta-analysis demonstrated that elemene plus chemotherapy was associated with a significant rise in the number of patients who reported improved tumor response, as well as a significant lower risk in patients with leucopenia as compared with chemotherapy alone. However, the pooled results failed to show favorable effects of elemene plus chemotherapy on survival rate compared with chemotherapy alone. This study suggested that elemene might enhance effectiveness of chemotherapy in cancer therapy.

show abstract

DC-CIK cell therapy combined with transcatheter arterial chemoembolization and radiofrequency ablation for treatment of small hepatocellular carcinoma

Cited by 6 publications

References 0 publications

Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review

Autologous transplantation of cytokine-induced killer cells as an adjuvant therapy for hepatocellular carcinoma in Asia: an update meta-analysis and systematic review

Is Adjuvant Cellular Immunotherapy Essential after TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma? A Systematic Meta-Analysis of Studies Including 1774 Patients

Elemene, One Ingredient of a Chinese Herb, Against Malignant Tumors: A Literature-based Meta-analysis

Contact Info

Product

Resources

About